Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Blood (2012) 120 (21): 2680.

https://doi.org/10.1182/blood.V120.21.2680.2680

Published: 2012

Journal Articles

Immunophenotypic Characteristics of CD34+ Cells According to Genetic Markers in Acute Myeloid Leukemias with Normal Karyotype.

Mauricio A Chandía, MD, Ma Belén Vidriales, MD, PhD, Carmen Chillón, PhD, Marcos González, MD, PhD, Norma Gutiérrez, MD, PhD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): 2554.

https://doi.org/10.1182/blood.V120.21.2554.2554

Published: 2012

Journal Articles

Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14.

Ana E Rodríguez, Jose Ángel Hernández-Rivas, Alberto Risueño, Encarna Fermiñán, Natalia de las Heras, Alfonso Garcia de Coca, Carlos Aguilar, Juan Nicolás Rodríguez, Josefina Galende, Javier de las Rivas, Jesús F San Miguel, MD, Marcos González, Jesús M Hernández-Rivas

Blood (2012) 120 (21): 2871.

https://doi.org/10.1182/blood.V120.21.2871.2871

Published: 2012

Journal Articles

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

Blood (2012) 120 (21): 3142.

https://doi.org/10.1182/blood.V120.21.3142.3142

Published: 2012

Journal Articles

A Targeted Resequencing Study Allows the Detection of a Common Polymorphism At Mirna-223 Binding Site in 3′Untranslated Region Which Deregulates HSP90B1 Expression in Chronic Lymphocytic Leukemia

Ana E Rodríguez, Dalia Qwaider, Rocío Benito, PhD, Irena Misiewicz-Krzeminska, María Hernández-Sánchez, M Eugenia Sarasquete, Jesús F San Miguel, MD, Jose Ángel Hernández-Rivas, Norma Gutierrez, Jesús M Hernández-Rivas

Blood (2012) 120 (21): 1776.

https://doi.org/10.1182/blood.V120.21.1776.1776

Published: 2012

Journal Articles

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Blood (2012) 120 (21): 334.

https://doi.org/10.1182/blood.V120.21.334.334

Published: 2012

Journal Articles

Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease

Lorenzo Melchor, PhD, Brian A Walker, BSc, PhD, Christopher P Wardell, PhD, Annamaria Brioli, MD, Martin F Kaiser, MD, Lucía López-Corral, MD, Sean Humphray, Lisa Murray, Mark Ross, David Bentley, Ramón García-Sanz, Jesús F San Miguel, MD, PhD, Faith E. Davies, MD, David Gonzalez, PhD, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 3941.

https://doi.org/10.1182/blood.V120.21.3941.3941

Published: 2012

Journal Articles

Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes

Blood (2012) 120 (21): 3827.

https://doi.org/10.1182/blood.V120.21.3827.3827

Published: 2012

Journal Articles

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antonio Garcia-Gomez, Dalia Quwaider, Enrique M Ocio, MD, PhD, Laura San-Segundo, Teresa Paíno, Juan F Blanco, Allison J Berger, PhD, Atanasio Pandiella, MD, PhD, Jesús F San-Miguel, MD, PhD, Mercedes Garayoa

Blood (2012) 120 (21): 4014.

https://doi.org/10.1182/blood.V120.21.4014.4014

Published: 2012

Journal Articles

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Blood (2012) 120 (21): 749.

https://doi.org/10.1182/blood.V120.21.749.749

Published: 2012

Journal Articles

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

Meletios A. Dimopoulos, MD, Martha Q Lacy, MD, Philippe Moreau, MD, Katja C Weisel, MD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Anne Banos, MD, Albert Oriol, MD, Xin Yu, PhD, Lars Sternas, MD, Christian J. Jacques, MD, Mohamed Zaki, MD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): LBA-6.

https://doi.org/10.1182/blood.V120.21.LBA-6.LBA-6

Published: 2012

Journal Articles

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Miguel Alcoceba, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig, M. Eugenia Sarasquete, M. Carmen Chillón, Cristina Jiménez, Rocío Corral, Eva González-Barca, M. Dolores Caballero, Jesús F. San Miguel, Ramón García-Sanz, Marcos González

Blood (2012) 120 (21): 1589.

https://doi.org/10.1182/blood.V120.21.1589.1589

Published: 2012

Journal Articles

Prognostic Impact of the Number of Methylated Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemias Treated with 5-Azacytidine

María Abáigar, Fernando Ramos, MD, PhD, MPH, Rocío Benito, PhD, María Díez-Campelo, MD, PhD, Javier Sánchez-del-Real, MD, Lourdes Hermosin, MD, Juan N Rodríguez, MD, Carlos Aguilar, MD, Isabel Recio, MD, Jose M Alonso, MD, Natalia de-las-Heras, MD, Marta Megido, MD, Marta Fuertes, MD, Consuelo Cañizo, MD, PhD, Jesús M Hernández, MD, PhD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): 1717.

https://doi.org/10.1182/blood.V120.21.1717.1717

Published: 2012

Journal Articles

Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Enrique M Ocio, MD, PhD, Pilar Herrera, MD, PhD, Teresa Olave, MD, Salut Brunet, Albert Oriol, Maria-Pilar Martínez-Sánchez, Miguel A. Sanz, MD, PhD, Marta Mateos, MD, Pilar Aliseda, MD, Ivo J. Winiger, MD, Sushant Hardikar, Maria Victoria Mateos, MD, PhD, Javier Lopez, Jesús F. San-Miguel, MD, PhD

Blood (2012) 120 (21): 1512.

https://doi.org/10.1182/blood.V120.21.1512.1512

Published: 2012

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

Blood (2011) 118 (21): 3938.

https://doi.org/10.1182/blood.V118.21.3938.3938

Published: 2011

Journal Articles

Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control

Roberto J. Pessoa Magalhaes, María-Belén Vidriales, Bruno Paiva, Maria-Victoria Mateos, Norma C. Gutierrez, Ramón García-Sanz, Juan F Blanco, Jose Hernández, Natalia de las Heras, Joaquin Martinez, MD, Elaine Sobral Costa, MD, PhD, Angelo Maiolino, MD, PhD, M. Nucci, MD, PhD, Javier De La Rubia, Juan-Jose Lahuerta, MD, Alberto Orfao, MD, PhD, Jesús F. San Miguel, Sr., MD, PhD

Blood (2011) 118 (21): 810.

https://doi.org/10.1182/blood.V118.21.810.810

Published: 2011

Journal Articles

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Blood (2011) 118 (21): 3976.

https://doi.org/10.1182/blood.V118.21.3976.3976

Published: 2011

Journal Articles

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Blood (2011) 118 (21): 1412.

https://doi.org/10.1182/blood.V118.21.1412.1412

Published: 2011

Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS

Blood (2011) 118 (21): 1377.

https://doi.org/10.1182/blood.V118.21.1377.1377

Published: 2011

NARROW

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Immunophenotypic Characteristics of CD34+ Cells According to Genetic Markers in Acute Myeloid Leukemias with Normal Karyotype.

Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14.

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

A Targeted Resequencing Study Allows the Detection of a Common Polymorphism At Mirna-223 Binding Site in 3′Untranslated Region Which Deregulates HSP90B1 Expression in Chronic Lymphocytic Leukemia

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease

Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Prognostic Impact of the Number of Methylated Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemias Treated with 5-Azacytidine

Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only